A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901)-Reference-Cited by-同舟云学术

A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901)

Published:2014-04 Issue:1 Volume:84 Page:67-72
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Murakami Haruyasu^ORCID,Yamamoto Nobuyuki,Shibata Taro,Takeda Koji,Ichinose Yukito,Ohe Yuichiro,Yamamoto Noboru,Takeda Yuichiro,Kudoh Shinzoh,Atagi Shinji,Satouchi Miyako,Kiura Katsuyuki,Nogami Naoyuki,Endo Masahiro,Watanabe Hirokazu,Tamura Tomohide

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference22 articles.

1. Small-cell lung cancer;Jackman;Lancet,2005

2. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer;Noda;N Engl J Med,2002

3. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer;Hanna;J Clin Oncol,2006

4. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124;Lara;J Clin Oncol,2009

5. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide;Turrisi;N Engl J Med,1999

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of second-line chemotherapy in patients with pulmonary large cell neuroendocrine carcinoma;Scientific Reports;2024-04-01

2. A Case of Treatment-resistant Extensive-disease Small-cell Lung Cancer with Multiple Liver Metastases Shrunk by Whole Liver Radiotherapy;Haigan;2023-12-20

3. Safety and efficacy of amrubicin with primary prophylactic pegfilgrastim as second‐line chemotherapy in patients with small cell lung cancer;Thoracic Cancer;2023-10-24

4. Reconsidering the Cutoff Value for Sensitive and Refractory Relapses in Extensive-Stage SCLC in the Era of Immunotherapy;Journal of Thoracic Oncology;2023-09

5. Influencing factors of efficacy and long‐term use of amrubicin in patients with small cell lung cancer;Thoracic Cancer;2023-03-30